Lupin Pharmaceuticals Inc, the Mumbai-based Lupin Ltd’s US subsidiary, has launched its amlodipine and valsartan tablets, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which are the AB rated generic equivalent of Novartis Pharmaceuticals Corporation’s Exforge tablets. Lupin had received final approval from the US Food and Drug Administration (FDA) for the product on March 31, 2015. According to IMS MAT December, 2014, Exforge tablets had US sales of $ 414.9 million.
Lupin’s amlodipine and valsartan tablet is the combination tablet of amlodipine (a dihydropyridine calcium channel blocker) and valsartan (an angiotensin II receptor blocker). Lupin’s amlodipine and valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Lupin’s amlodipine and valsartan tablet is the combination tablet of amlodipine (a dihydropyridine calcium channel blocker) and valsartan (an angiotensin II receptor blocker). Lupin’s amlodipine and valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.